Research Article| Volume 29, ISSUE 4, 104645, April 2020

Download started.


Modafinil in Recovery after Stroke (MIRAS): A Retrospective Study


      Background and Purpose: Acute rehabilitation is known to enhance stroke recovery. However, poststroke lethargy and fatigue can hinder participation in rehabilitation therapies. We hypothesized that in patients with moderate to severe stroke complicated by poststroke fatigue and lethargy early stimulant therapy with modafinil increases favorable discharge disposition defined as transfer to acute inpatient rehabilitation or home. Methods: We retrospectively reviewed a cohort of patients with acute stroke admitted to the stroke service over a 3-year period. All patients 18 years or older with confirmed ischemic or hemorrhagic stroke, an NIHSS greater than or equal to 5 and documentation of fatigue/lethargy in clinical documentation were included. We compared patients that were treated with modafinil 50-200 mg to those managed with standard care. The primary outcome measure was discharge disposition. Secondary outcome was 90 day modified Rankin score (mRS). Statistical significance was determined using chi-square test for association and logistic regression models. Logistic regression models were derived in 2 ways with both raw data and an adjusted model that accounted for age, sex, and NIHSS score to account for the lack of randomization. Results: This study included 199 stroke patients (145 ischemic, 54 hemorrhagic). Seventy-two (36.2%) were treated with modafinil and 129 (64.8%) were discharged to acute inpatient rehabilitation, while none were recommended for discharge home. Median NIHSS for modafinil patients was 13.5 versus 11 for standard care patients (P = .059). In adjusted models, modafinil was associated with higher odds of favorable discharge disposition (OR 2.00, 95% CI 1.01-3.95). Favorable outcome at 90 days defined as mRS less than or equal to 2 occurred more frequently with modafinil (5.6% versus 3.3%) but this did not achieve statistical significance (P > .1). These results occurred despite the modafinil group requiring longer ICU stays and having more in-hospital complications such as infections and need for percutaneous gastrostomy tubes. The benefit of modafinil was seen across all subgroups except those with severe stroke (NIHSS ≥ 15). There were no significant adverse events associated with modafinil administration. Conclusions: Modafinil use in acute in-hospital stroke patients with moderate stroke complicated by lethargy and fatigue was associated with improved discharge disposition. Randomized controlled trials are needed to further study the safety, efficacy, and long-term effects of modafinil in this patient population.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Maulden S.A.
        • Gassaway J.
        • Horn S.D.
        • et al.
        Timing of initiation of rehabilitation after stroke.
        Arch Phys Med Rehabil W.B. Saunders. 2005; 86: 34-40
        • Naess H.
        • Lunde L.
        • Brogger J.
        The triad of pain, fatigue and depression in ischemic stroke patients: the Bergen Stroke Study.
        Cerebrovasc Dis Karger Publishers. 2012; 33: 461-465
        • Carlsson G.E.
        • Forsberg-Wärleby G.
        • Möller A.
        • et al.
        Comparison of life satisfaction within couples one year after a partner's stroke.
        J Rehabil Med. 2007; 39: 219-224
        • Lynch J.
        • Mead G.
        • Greig C.
        • et al.
        Fatigue after stroke: the development and evaluation of a case definition.
        J Psychosom Rese. 2007; 63: 539-544
        • van Eijsden H.M.
        • van de Port I.G.L.
        • Visser-Meily J.M.A.
        • et al.
        Poststroke fatigue: who is at risk for an increase in fatigue?.
        Stroke Res Treat. 2012; 2012 (–8)863978
        • Lerdal A.
        • Gay C.L.
        Fatigue in the acute phase after first stroke predicts poorer physical health 18 months later.
        Neurology. 2013; 81: 1581-1587
        • Schuster C.
        • Maunz G.
        • Lutz K.
        • et al.
        Dexamphetamine improves upper extremity outcome during rehabilitation after stroke: a pilot randomized controlled trial.
        5 ed. Neurorehabil Neural Repair. 25. SAGE PublicationsSage CA, Los Angeles, CA2011: 749-755
        • Horn S.D.
        • DeJong G.
        • Smout R.J.
        • et al.
        Stroke rehabilitation patients, practice, and outcomes: is earlier and more aggressive therapy better?.
        Arch Phys Med Rehabil. 2005; 86: S101-S114
        • Bivard A.
        • Lillicrap T.
        • Krishnamurthy V.
        • et al.
        MIDAS (Modafinil in Debilitating Fatigue After Stroke): A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial. 48. Stroke American Heart Association, Inc, 2017: 1293-1298
        • Han J.
        • Chen D.
        • Liu D.
        • et al.
        Modafinil attenuates inflammation via inhibiting Akt/NF-κB pathway in apoE-deficient mouse model of atherosclerosis. 67. Inflammopharmacology Springer International Publishing, 2017: 554 (–393)
        • Zolkowska D.
        • Andres-Mach M.
        • Prisinzano T.E.
        • et al.
        Modafinil and its metabolites enhance the anticonvulsant action of classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model.
        Psychopharmacology (Berl). 2015; 232: 2463-2479
        • Cao J.
        • Slack R.D.
        • Bakare O.M.
        • et al.
        Novel and high affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) analogues as atypical dopamine transporter inhibitors.
        J Med Chem. 2016; 59: 10676-10691
        • Ferraro L.
        • Antonelli T.
        • O'Connor W.T.
        • et al.
        The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission.
        Neurosci Lett. 1998; 253: 135-138
        • Kaplan S.
        • Goehring E.L.
        • Melamed-Gal S.
        • et al.
        Modafinil and the Risk of Cardiovascular Events: Findings from Three US Claims Databases. 27. Pharmacoepidemiol Drug Saf John Wiley & Sons, Ltd, 2018: 1182-1190
        • Martinsson L.
        • Eksborg S.
        Drugs for Stroke Recovery. 21. Drugs Aging Springer International Publishing, 2004: 67-79